Costimulatory molecules as vaccine adjuvants: to 4-1BB or not to 4-1BB?

Rahman, Khalidur; Iyer, Smita S.

doi:10.1038/cmi.2014.90

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, DNAX-activation protein 12 (DAP12) and DAP10 have been selected as intracellular signaling domains, and CD3ζ appears to be a better signaling domain than DAP10 [15] , whereas DAP12 may better activate signaling than CD3ζ for NK cells [26] . For second-generation CARs, the important costimulatory molecule 4-1-BB combines with CD3ζ as an intracellular domain, which significantly enhances the targeted lysis of CAR-NK cells [27][28][29] . However, the combination of CAR constructs for optimal NK cell activation may depend on the tumor type or target antigen [27] .…”

Section: Current Progress In the Use Of Car-nk Cells From Investigatmentioning

confidence: 99%

Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy

2017

View full text Add to dashboard Cite

Natural killer (NK) cells are potential effector cells in cell-based cancer immunotherapy, particularly in the control of hematological malignancies. The chimeric antigen receptor (CAR) is an artificially modified fusion protein that consists of an extracellular antigen recognition domain fused to an intracellular signaling domain. T cells genetically modified with a CAR have demonstrated remarkable success in the treatment of hematological cancers. Compared to T cells, CAR-transduced NK cells (CAR-NK) exhibit several advantages, such as safety in clinical use, the mechanisms by which they recognize cancer cells, and their abundance in clinical samples. Human primary NK cells and the NK-92 cell line have been successfully transduced to express CARs against both hematological cancers and solid tumors in pre-clinical and clinical trials. However, many challenges and obstacles remain, such as the ex vivo expansion of CAR-modified primary NK cells and the low transduction efficiency of NK cells. Many strategies and technologies have been developed to improve the safety and therapeutic efficacy in CAR-based immunotherapy. Moreover, NK cells express a variety of activating receptors (NKRs), such as CD16, NKG2D, CD226 and NKp30, which might specifically recognize the ligands expressed on tumor cells. Based on the principle of NKR recognition, a strategy that targets NKRs is rapidly emerging. Given the promising clinical progress described in this review, CAR- and NKR-NK cell-based immunotherapy are likely promising new strategies for cancer therapy.

show abstract

Section: Current Progress In the Use Of Car-nk Cells From Investigatmentioning

confidence: 99%

Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy

2017

View full text Add to dashboard Cite

show abstract

“…T cells may become anergic in the absence of this costimulation, resulting in tolerance or lack of response to the antigen, even if the antigen is adequately presented [ 57 ]. Researchers have used this process to create immunotherapeutic strategies and vaccines against specific diseases [ 58 , 59 ].…”

Section: P2x7 In Antigenic Presentation and T-cell Activation By Dend...mentioning

confidence: 99%

P2X7 Receptor in Dendritic Cells and Macrophages: Implications in Antigen Presentation and T Lymphocyte Activation

Acuña-Castillo,

Escobar,

García-Gómez

et al. 2024

IJMS

View full text Add to dashboard Cite

The P2X7 receptor, a member of the P2X purinergic receptor family, is a non-selective ion channel. Over the years, it has been associated with various biological functions, from modulating to regulating inflammation. However, its emerging role in antigen presentation has captured the scientific community’s attention. This function is essential for the immune system to identify and respond to external threats, such as pathogens and tumor cells, through T lymphocytes. New studies show that the P2X7 receptor is crucial for controlling how antigens are presented and how T cells are activated. These studies focus on antigen-presenting cells, like dendritic cells and macrophages. This review examines how the P2X7 receptor interferes with effective antigen presentation and activates T cells and discusses the fundamental mechanisms that can affect the immune response. Understanding these P2X7-mediated processes in great detail opens up exciting opportunities to create new immunological therapies.

show abstract